The screen­ing test for cer­vi­cal can­cer pre­ven­tion Gyn­Tect is now avail­able to doc­tors and patients in China, the world’s most pop­u­lous coun­try, under exclu­sive license. Gyn­Tect was devel­oped by the oncg­nos­tics GmbH and is already approved in Europe. It is the first prod­uct of its kind that can be used for abnor­mal find­ings in China. Gyn­Tect can now help mil­lions of women there to take treat­ment mea­sures quickly or pre­vent them from being overtreated. Above all, they will receive a reli­able diag­no­sis much faster than usual. 

How Gyn­Tect works

The Gyn­Tect mol­e­c­u­lar bio­log­i­cal test devel­oped by oncg­nos­tics clar­i­fies at an early stage whether a patient with con­spic­u­ous find­ings is devel­op­ing or even already has cer­vi­cal can­cer that needs to be treated. The clar­i­fi­ca­tion test detects changes in the DNA (so-called methy­la­tions), which only occur if cer­vi­cal can­cer is present or devel­op­ing. To carry out the test, all that is needed is a smear test like the ones taken by a gyne­col­o­gist as part of reg­u­lar screen­ing. So far, Gyn­Tect has detected all cases of women with cer­vi­cal cancer. 

How Gyn­Tect is used in China

“We are delighted that GeneoDx has been able to approve Gyn­Tect, the first DNA methy­la­tion-based prod­uct for the early detec­tion of cer­vi­cal can­cer in China. This is a great mile­stone for GeneoDx, but also for all Chi­nese women who can now have access to such an inno­v­a­tive prod­uct!” said Xiaokai Xia, Man­ag­ing Direc­tor of Shang­hai GeneoDx. GeneoDx is a sub­sidiary of the Sinopharm Group. In China, more than 100,000 new cases of can­cer and almost 60,000 deaths are reported every year. Stud­ies have shown that around 17% of women in China test pos­i­tive for human papil­lo­mavirus (HPV) dur­ing cer­vi­cal can­cer screen­ings. This cor­re­sponds to around 70 mil­lion patients whose find­ings have yet to be clar­i­fied at great expense. This is because only a few women with an HPV infec­tion develop cer­vi­cal can­cer. Gyn­Tect detects pre­cisely these cases. 

Advan­tages of GynTect

Gyn­Tect pro­vides fast and reli­able exam­i­na­tion results and gives affected women cer­tainty just as quickly about the best way to pro­ceed after an abnor­mal pre­lim­i­nary exam­i­na­tion result. Risk assess­ment is made much eas­ier: on the one hand, unnec­es­sary oper­a­tions can be avoided and, on the other, the chances of suc­cess­ful treat­ment mea­sures can be increased. Accord­ing to GeneoDx, the Chi­nese coop­er­a­tion part­ner of oncg­nos­tics, the num­ber of refer­rals for cer­vi­cal endoscopy (col­poscopy) can be reduced by more than 60% through the use of Gyn­Tect. In col­poscopy, the cervix is exam­ined for abnor­mal­i­ties and changes using a spe­cial micro­scope and pro­ce­dure. In most cases, gyne­col­o­gists in pri­vate prac­tice are unable to per­form this them­selves. The woman con­cerned must there­fore wait for an appoint­ment at a spe­cial­ist consultation. 

In addi­tion to numer­ous EU coun­tries and the Peo­ple’s Repub­lic of China, Gyn­Tect is already dis­trib­uted in Brazil and Mex­ico. oncg­nos­tics GmbH is con­stantly work­ing on con­clud­ing suit­able coop­er­a­tion agree­ments for other coun­tries worldwide. 

“This is another suc­cess for our bm|t port­fo­lio and once again demon­strates the global stand­ing of the life sci­ence clus­ter in Jena. We are par­tic­u­larly pleased that oncg­nos­tics is already in advanced talks with other part­ners for approval in the USA.” Says Michael Thiele, Invest­ment Man­ager at bm|t. Women who have abnor­mal find­ings from cer­vi­cal can­cer screen­ing can talk to their gyne­col­o­gist about Gyn­Tect or con­tact oncg­nos­tics directly: 

kontakt@oncgnostics.com

+493641 5548500

About oncg­nos­tics GmbH:

Jena-based oncg­nos­tics GmbH spe­cial­izes in the early detec­tion of can­cer. Its tests detect changes that are char­ac­ter­is­tic of the DNA of can­cer cells. Founded in 2012, the com­pany launched Gyn­Tect on the mar­ket in 2015. oncg­nos­tics GmbH is also research­ing clar­i­fi­ca­tion tests for other types of can­cer. You can find detailed infor­ma­tion at www.oncgnostics.com.

Free image mate­r­ial: www.tower-pr.com/oncgnostics

About GeneoDx and SINOPHARM Group:

GeneoDx is a sub­sidiary of Sinopharm Group (China National Phar­ma­ceu­ti­cal Group Co Ldt.). As one of the coun­try’s lead­ing health­care com­pa­nies, Sinopharm has estab­lished a nation­wide logis­tics and dis­tri­b­u­tion net­work for phar­ma­ceu­ti­cals, med­ical devices and equip­ment. From research and devel­op­ment, man­u­fac­tur­ing, dis­tri­b­u­tion to tech­ni­cal and finan­cial ser­vices, the Group cov­ers the entire spec­trum of the indus­try. Sinopharm is ranked 80^th on the Global For­tune list, has more than 120,000 employ­ees and a turnover of 103.2 bil­lion euros in 2021. 

About bm|t beteili­gungs­man­age­ment thürin­gen gmbh: 

bm|t is one of the top addresses for invest­ments in Thuringia. The cap­i­tal entrusted to bm|t is invested prof­itably in start-up teams and com­pa­nies in the Free State. This is how inno­va­tions and eco­nomic growth are financed in Thuringia. bm|t cur­rently man­ages nine funds with a total vol­ume of over EUR 360 mil­lion and invests in inno­v­a­tive com­pa­nies in almost all sec­tors and in all phases of cor­po­rate devel­op­ment — both in the start-up and growth phases as well as in com­pany suc­ces­sion sit­u­a­tions.

www.bm-t.com